Sponsored Content

Symrise announced a cash offer to the shareholders of Probi

18 Feb 2025

‒ Symrise has announced a public offer to the shareholders of Probi AB (publ). The shares in Probi are traded on Nasdaq Stockholm, Mid Cap.

‒ Symrise is Probi’s largest shareholder representing approximately 69.7 per cent of the outstanding capital and votes.

Symrise announced a cash offer to the shareholders of Probi
Image courtesy of Symrise AG

Symrise has today announced a cash offer to the shareholders of Probi, a global biotics solutions company, focused on researching, manufacturing, and delivering biotics for supplements and functional food. Symrise is Probi’s largest shareholder and has been a shareholder since 2012. Through its active involvement, Symrise has deep knowledge and understanding of Probi, its operations, and the market it operates in. Symrise has a long-term belief in Probi since the company has a very attractive product offering that makes the health-enhancing benefits of probiotics available to people everywhere, and a fantastic global team. Symrise believes that there is great potential to elevate Probi to the next level under the Symrise group, as a key driver to Symrise’s focused strategy in health.

Probi to realize their investment at an attractive valuation. Symrise has been a long-term sharehold-er in Probi and has acted with a long-term perspective in the best interest of the Company, its teams and shareholders. Today’s offer to Probi’s shareholders reflects Symrise’s conviction that Probi would see its prospects enhanced in a private environment. We are pleased that the offer has re-ceived the full support from Probi’s two other largest shareholders. As a global leader in products supporting health, Symrise is ideally placed to leverage and capitalize on the strong foundation the Probi team has built. By joining forces, we will further strengthen our respective capabilities to serve the market with leading customized solutions, unlocking even greater value for customers globally.”

Further information about the offer including the offer press release that Symrise published today is available at: www.symrise.com/probi.
 

Read More

Related news

PharmaLinea's product awarded for innovation in bone and joint health

PharmaLinea's product awarded for innovation in bone and joint health

11 Mar 2025

>Your< Arthro Ease Capsules received the Annual Bone and Joint Health Award at the Functional Foods for Wellness Summit 2025

Read more 
PureGreenLineTM Sustainability and Innovation in Nutraceuticals- is a state-of-the-art-botanical extraction technology

PureGreenLineTM Sustainability and Innovation in Nutraceuticals- is a state-of-the-art-botanical extraction technology

11 Mar 2025

PureGreenLineTM revolutionizes botanical extraction with a cutting-edge, eco-friendly approach that meets the highest standards of quality and purity. Designed for forward-thinking manufacturers, this breakthrough process provides premium extract...

Read more 
Your partner in nutraceutical e-commerce

Your partner in nutraceutical e-commerce

11 Mar 2025

E-commerce has become one of the most prominent sales channels in the dietary supplement market. The convenience of buying them at the click of a button, or even subscribing to receive them periodically, as platforms such as Amazon allow, is an attr...

Read more 
ACT strengthens its focus on the animal feed industry with new expert

ACT strengthens its focus on the animal feed industry with new expert

10 Mar 2025

Atlantic Chemicals Trading GmbH (ACT), an established distributor of raw materials for the food, cosmetics and pharmaceutical industries based in Hamburg, is further expanding its presence in the animal feed sector by hiring Andreas Stein, who bring...

Read more 
FERTIBIOME® | EVIDENCIA CLÍNICA (2)

FERTIBIOME® | EVIDENCIA CLÍNICA (2)

9 Mar 2025

Ligilactobacillus salivarius PS11610 mejora el éxito de la fertilización mediante FIV: un análisis retrospectivo preliminar

Read more 
FERTIBIOME® | EVIDENCIA CLÍNICA (1): PAREJAS EN TRATAMIENTO DE REPRODUCCIÓN ASISTIDA

FERTIBIOME® | EVIDENCIA CLÍNICA (1): PAREJAS EN TRATAMIENTO DE REPRODUCCIÓN ASISTIDA

9 Mar 2025

Ligilactobacillus salivarius PS11610 ejerce un efecto sobre el perfil microbiano e inmunológico de parejas con infertilidad desconocida.

Read more 
The Power of Vitamin D: Why Consistency Matters

The Power of Vitamin D: Why Consistency Matters

7 Mar 2025

The primary function of vitamin D is to slow down cell division while promoting cell differentiation. When these two effects are combined, vitamin D exhibits an anti-tumor mechanism. Tumors proliferate uncontrollably because their cells lose the a...

Read more 
The Truth About Vitamin C: Are You Really Getting Enough?

The Truth About Vitamin C: Are You Really Getting Enough?

7 Mar 2025

Your health is in your hands – make Vitamin C a priority today!The Vitamin C is one of the most well-known nutrients, yet most people don’t fully understand its role.The modern diets, stress, and environmental factors impact Vitamin C levels.

Read more 
Scientific study shows BENEO’s Palatinose™ as a bedtime drink improves aspects of sleep

Scientific study shows BENEO’s Palatinose™ as a bedtime drink improves aspects of sleep

7 Mar 2025

A new randomised controlled trial, conducted by Gaylor et al, demonstrates that BENEO’s slow and sustained release carbohydrate Palatinose™ improves aspects of sleep when consumed as a bedtime drink. By leading to more balanced blood glucose level...

Read more 
Study shows BENEO’s Palatinose™ stimulates the release of GLP-1 in overweight adults

Study shows BENEO’s Palatinose™ stimulates the release of GLP-1 in overweight adults

6 Mar 2025

A new study, led by Prof. Andreas Pfeiffer (Zhang et al.), demonstrates that intake of the naturally sourced, smart carbohydrate Palatinose™ stimulates the release of beneficial gut hormones including GLP-1 in overweight adults, even if its ...

Read more